Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort | Zendy

Jason A. Trubiano | Zendy; A.M. Crowe | Zendy; Leon J. Worth | Zendy; Karin Thursky | Zendy; Monica A. Slavin | Zendy

Open Access

Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort

Author(s) -

Jason A. Trubiano,

A.M. Crowe,

Leon J. Worth,

Karin Thursky,

Monica A. Slavin

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku529

Subject(s) - cyp2c19 , pharmacogenomics , voriconazole , genotyping , medicine , cohort , test (biology) , oncology , pharmacology , biology , genetics , genotype , gene , antifungal , cytochrome p450 , dermatology , metabolism , paleontology

The clinical utility of pharmacogenomic testing in haematology patients with invasive fungal disease (IFD) receiving azole therapy has not been defined. We report our experience with CYP2C19 testing in haematological patients requiring voriconazole therapy for IFD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research